North East and North Cumbria
ICS Formulary
ICS Formulary
1 Gastro-intestinal system
01-05-03 Cytokine inhibitors
| Adalimumab |
|
Formulary
|
|
 NICE TA187: Crohn’s disease - infliximab and adalimumab NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
|
| Golimumab |
|
Formulary
|
|
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
|
|
| Infliximab Remicade®, Inflectra®, Remsima® |
|
Formulary
|
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab NICE TA187: Crohns disease - infliximab & adalimumab NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis  NTAG recommends the use of infliximab biosimilars as an option where the originator product (Remicade®) would normally be prescribed |
|
|
| Mirikizumab Omvoh® |
|
Formulary
|
|
|
NICE TA925: Mirikizumab for treating moderately to severely active ulcerative colitis |
|
|
| Risankizumab Skyrizi® |
|
Formulary
|
|
|
NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease NICE TA998: Risankizumab for treating moderately to severely active ulcerative colitis |
|
|
| Ustekinumab Stelara® |
|
Formulary
|
|
|
MHRA Drug Safety Update (Jan 2015): Ustekinumab (Stelara): risk of exfoliative dermatitis NICE TA456 Ustekinumab for moderately to severely active Crohn’s disease after previous treatment NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
|
|
| Ozanimod Zeposia® |
|
Formulary
|
|
|
NICE TA 828: Ozanimod for treating moderately to severely active ulcerative colitis |
|
|
| Dupilumab Dupixent® |
|
Non Formulary
|
|
|
NICE TA938: Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) |
|
Links
- Newcastle, North Tyneside, Northumberland & Gateshead - Guidelines for Monitoring of Immune Modifying Drugs (IMDs) in Stable Adult Patients (excluding post transplantation) in Primary and Secondary Care
- County Durham and Darlington Shared Care Guideline: Ciclosporin
- County Durham and Darlington Shared Care Guideline: Methotrexate
- Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities
- MHRA Drug Safety Alert March 2020: Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections
- MHRA Drug Safety Alert Oct 2021: Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies
- MHRA Drug Safety Update (April 2023): Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA Drug Safety Update (August 2023): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions
- MHRA Drug Safety Update (Jan 2015): Ustekinumab (Stelara): risk of exfoliative dermatitis
- MHRA Drug Safety Update (Sept 2020): Methotrexate once weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing
- MHRA Drug Safety Update April 2023: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA Drug Safety Update April 2023: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA Drug Safety Update May 2019: Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing
NENC Shared Care Protocol - Azathioprine and mercaptopurine within adult services (non-transplant indications)- NENC Shared Care Protocol - Azathioprine and mercaptopurine within adult services (non-transplant indications)
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG129: Crohn’s disease: management
- NICE NG130: Ulcerative colitis: management
- NICE NG147: Diverticular disease: diagnosis and management
- NICE TA 828: Ozanimod for treating moderately to severely active ulcerative colitis
- NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
- NICE TA187: Crohn’s disease - infliximab and adalimumab
- NICE TA187: Crohns disease - infliximab & adalimumab
- NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
- NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
- NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
- NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
- NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
- NICE TA456 Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
- NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
- NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
- NICE TA792: Filgotinib for treating moderately to severely active ulcerative colitis
- NICE TA826: Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)
- NICE TA856: Upadacitinib for treating moderately to severely active ulcerative colitis
- NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease
- NICE TA905: Upadacitinib for previously treated moderately to severely active Crohn’s disease
- NICE TA925: Mirikizumab for treating moderately to severely active ulcerative colitis
- NICE TA938: Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)
- NICE TA956: Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over
- NICE TA998: Risankizumab for treating moderately to severely active ulcerative colitis
- NTAG recommends the use of infliximab biosimilars as an option where the originator product (Remicade®) would normally be prescribed
- NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence